OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research in Clinical Rheumatology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Diagnosing rheumatoid arthritis: challenges and opportunities	118
Bone health as a co-morbidity of chronic kidney disease	71
Clinical and molecular significance of genetic loci associated with psoriatic arthritis	54
Editorial Board	53
Pain syndromes	37
Editorial Board	33
Assessment of disease activity and damage in SLE: Are we there yet?	33
Problems with “Problems with opioids beyond misuse”	30
Preface: Pediatric rheumatology	29
Structural disease modification in axial spondyloarthritis	28
Index	27
Advances in axial spondyloarthritis: Learning from the leaders	27
Cardiovascular disease and depression in psoriatic arthritis: Multidimensional comorbidities requiring multidisciplinary management	27
Rehabilitation interventions in osteoarthritis	25
How to implement guidelines and models of care	23
Advances in the maintenance of ANCA vasculitis remission	22
Steroid sparing in vasculitis: Myth or reality?	22
Novel therapies in axial spondyloarthritis	21
Systemic lupus erythematosus and damage: What has changed over the past 20 years?	20
Possible future avenues for myositis therapeutics: DM, IMNM and IBM	18
Change of the microvascularization in systemic sclerosis, a matter of air	18
Current treatments and recommendations for Psoriatic Arthritis	18
Employment outcomes in systemic sclerosis	17
Insights into the genetic landscape of systemic sclerosis	17
The importance of functional genomics studies in precision rheumatology	17

Functional capacity, sarcopenia, and bone health	17
Infection associated Vasculitides	16
A review of the advances in understanding the genetic basis of spondylarthritis and emerging clinical benefit	16
Biomarkers for osteoarthritis: Current status and future prospects	15
Pathogenesis of psoriatic arthritis	15
Botulinum toxin in the management of primary and secondary Raynaud's phenomenon	15
Modifiable risk factors for bone health & fragility fractures	15
Pain mechanisms for the practicing rheumatologist	15
Editorial Board	14
The inequity of global healthcare in pediatric rheumatology	14
Exploring the role of gut microbes in spondyloarthritis: Implications for pathogenesis and therapeutic strategies	14
38.3 Primary Immunodeficiencies: When is it not just “JIA”	14
Musculoskeletal manifestations of systemic lupus erythematosus	14
Access to rheumatologic care in tropical regions: Barriers and solutions	14
Antiphospholipid syndrome in children	14
Peripheral spondyloarthritis: What have we learned?	14
Editorial Board	13
Imaging in sarcoid disease	13
Tropical pyomyositis	13
Promise of rheumatoid arthritis therapy: From clinical deep remission to drug-free remission	13
Exercise in myositis: What is important, the prescription or the person?	13
Management of JIA associated uveitis	12
Osteoporosis in children and young adults	12
Explainable biology for improved therapies in precision medicine: AI is not enough	12
Calcium pyrophosphate deposition (CPPD) disease – Treatment options	11
The communication GAP between patients and clinicians and the importance of patient reported outcomes in Systemic Lupus Erythematosus	11
Pathophysiology and immunolgical basis of axial spondyloarthritis	10
The global burden of fragility fractures – what are the differences, and where are the gaps	10
Immunopathology of inflammatory rheumatic diseases	10
Education and training in tropical rheumatology	10
Pregnancy in systemic lupus erythematosus	10
Fecal incontinence and scleroderma: Pathogenesis and unmet needs	9
Psoriatic Arthritis: Current status	9
Clinical patterns of disease: From early systemic lupus erythematosus to late-onset disease	9
Environmental factors and rheumatic diseases	9
Granzyme K+ CD8 T cells in autoimmunity	9
Epidemiology of rheumatic diseases in tropical populations	9
Management of Takayasu arteritis	8
Management of interstitial lung disease (ILD) in myositis syndromes: A practical guide for clinicians	8
B cell activation and autoantibody production in autoimmune diseases	8
Editorial Board	8
A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc	8
Temporal artery biopsy	8
Innovations in systemic sclerosis	8
Relapsing polychondritis: Best Practice & Clinical Rheumatology	8
Risk for osteoporosis and fracture with glucocorticoids	8
Cardiac involvement in systemic sclerosis: Getting to the heart of the matter	8
The epidemiology of psoriatic arthritis: A literature review	8
Systemic lupus erythematosus and glucocorticoids: A never-ending story?	8
New advances in crystal arthritis	7

Response to kollas. Letter to the editor, “problems with opioids beyond misuse”	7
Index	7
Best practice and research advances in many aspects of rheumatology	7
What the rheumatologist needs to know about skin biopsy	7
Index	7
Index for PART A	7
Index	7
Editorial Board	7
Editorial Board	6
Editorial Board	6
Unmet needs in psoriatic arthritis	6
Vasculitis in the 21st century: From prayers to progress	6
Nutrients and Nocioception: Diet in the management of pain	5
Regenerative methods in osteoarthritis	5
Treatment advances in gout	5
Exploring the contribution of genetics on the clinical manifestations of systemic lupus erythematosus	5
Unmet need in the treatment of polymyalgia rheumatica and giant cell arteritis	5
Kidney involvement in systemic lupus erythematosus: From the patient assessment to a tailored treatment	5
Inclusion body myositis: The interplay between ageing, muscle degeneration and autoimmunity	4
Cardiovascular risk in vasculitis	4
Immune checkpoints in autoimmune vasculitis	4
Personalised medicine in juvenile dermatomyositis: From novel insights in disease mechanisms to changes in clinical practice	4
Pre-RA: Can early diagnosis lead to prevention?	4
Potential therapeutic targets of fibrosis in inflammatory rheumatic diseases	4
Pharmacogenetics of therapies in rheumatoid arthritis: An update	4
A lifelong journey: Long-term perspectives on Juvenile Idiopathic Arthritis	4
Advances in remission induction therapy for ANCA-associated vasculitis	4
Challenges and complications in juvenile localized scleroderma: A practical approach	3
The microbiome and systemic sclerosis: A review of current evidence	3
Current evidence and practical knowledge for ultrasound-guided procedures in rheumatology: Joint aspiration, injection, and other applications	3
Myofascial pain – A major player in musculoskeletal pain	3
Pain in osteoarthritis from a symptom to a disease	3
Role of rheumatoid arthritis registries worldwide: What have they taught us?	3
Infectious mimics of rheumatoid arthritis	3
Imaging of giant cell arteritis – recent advances	3
Idiopathic inflammatory myopathies: Progress, challenges, and future perspectives	3
Personalized medicine in rheumatoid arthritis: Combining biomarkers and patient preferences to guide therapeutic decisions	3
What's new on the horizon for rheumatoid arthritis management	3
Risk assessment tools for osteoporosis and fractures in 2022	3
Review for best practice in clinical rheumatology juvenile systemic sclerosis – Updates and practice points	3
Genetics of osteoarthritis	3
Index	2
Exploring osteoarthritis: Unraveling challenges, innovations, and hope for a better future	2
Musculoskeletal complications in sickle cell disease: Pathophysiology, diagnosis and management	2
When are patients with osteoarthritis referred for surgery?	2
Osteoporosis in 2022: Care gaps to screening and personalised medicine	2
Preface to practical procedures how to do	2
Horizon scan: State-of-the-art therapeutics for psoriatic arthritis	2
Review: Outcome measures in calcium pyrophosphate deposition	2
Implications of a diagnosis of rheumatoid arthritis in resource-poor countries	2
Use of Mendelian randomization to assess the causal status of modifiable exposures for rheumatic diseases	2
Translational implications of newly characterized pathogenic pathways in systemic lupus erythematosus	2
Editorial Board	2